Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$75.37M

FY 2025 · Annual

Investing Cash Flow

$43.38M

FY 2025 · Annual

-54.6% YoY

Financing Cash Flow

$30.05M

FY 2025 · Annual

-27.8% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Depreciation & Amortization789K621K530K340K(114K)
Deferred Income Tax1.45M0000
Stock-Based Compensation29.78M35.4M21.71M18.43M14.05M
Change in Working Capital(23.19M)(19.99M)31.42M(302K)28.27M
Accounts Receivables(9.62M)(5.08M)20.12M(3.8M)4.59M
Inventory(1.46M)(118K)1.18M(1.7M)701K
Accounts Payables(2.85M)1.17M350K1.98M(1.1M)
Other Working Capital(9.26M)(15.96M)9.76M3.21M24.09M
Other Non-Cash Items8.14M(294K)(3.28M)(69.53M)78.46M
Operating Cash Flow(107.12M)(149.55M)(92.72M)(127.49M)(75.37M)
Capital Expenditures(5.71M)(118K)0(142K)0
Acquisitions (Net)5.5M104.26M000
Purchases of Investments(45.23M)(226.02M)(159.15M)(58.82M)0
Sales of Investments192.78M121.88M167.09M154.44M43.38M
Other Investing Activities(5.5M)(104.26M)000
Investing Cash Flow141.84M(104.26M)7.94M95.47M43.38M
Debt Repayment60M0083.3M20.54M
Common Stock Issued9.9M189.76M1.12M1.45M9.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.75M3.98M0(43.11M)0
Financing Cash Flow73.65M193.74M1.12M41.65M30.05M
Effect of Forex Changes(48K)(488K)(34K)(11K)20K
Net Change in Cash108.32M(60.56M)(83.69M)9.62M(1.92M)
Free Cash Flow(112.83M)(149.67M)(92.72M)(127.63M)(75.37M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$196.0M
+ D&A-$114.0K
+ Stock-Based Comp$14.1M
+ Deferred Tax$0
+ Working Capital$28.3M
+ Other Non-Cash$78.5M
= Operating Cash Flow-$75.4M
- Capex$0
= Free Cash Flow-$75.4M

Analysis

FY2025 free cash flow is -$75.4M. FCF conversion is 38.4% of net income. Operating cash flow was -$75.4M, with capex of $0. The largest bridge item is Other Non-Cash at $78.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJul 17, 2026
SC 13G/ASC 13G/A filingJun 5, 2026
8-KCurrent reportMay 28, 2026
S-8S-8 filingMay 27, 2026
S-8S-8 filingMay 27, 2026

Does KPTI generate free cash flow?

Karyopharm Therapeutics Inc. (KPTI) generated -$75.37M of free cash flow in fiscal 2025.

How much operating cash flow does KPTI produce?

Operating cash flow was -$75.37M, before capital expenditures of $0.00.